As the healthcare provider landscape rapidly evolves to deliver on the promises of value-based care and efficiencies of scale, integrated delivery networks (IDNs) have emerged as a dominant force in the US market. Meanwhile, biopharmaceutical manufacturers have struggled to understand the needs of IDNs and how to engage with them in a meaningful way.
Leveraging Health Strategies Insights’ proprietary syndicated industry research on IDNs, combined with EVERSANA™ MANAGEMENT CONSULTING real-world experience of helping biopharmaceutical brands better address the needs of this critical customer, this article will examine three key elements:
• The rise and evolution of IDNs
• The challenges and implications for biopharma manufacturers attempting to meaningfully engage with IDNs
• Six key institutional channel trends manufacturers should be watching in order to meet the needs of IDNs
Download the full White Paper
Health Strategies Insights by EVERSANA gives you an advanced set of capabilities, frameworks, and methods. These are all derived from a robust stakeholder panel, providing critical answers to your specific payer marketing and market…